# Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis

> **NCT05445076** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Biocad** · enrollment: 250 (estimated)

## Conditions studied

- Axial Spondyloarthritis

## Interventions

- **BIOLOGICAL:** anti-TRBV9 monoclonal antibody, low dose
- **BIOLOGICAL:** anti-TRBV9 monoclonal antibody, high dose
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT05445076
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-19
- **Primary completion:** 2025-12
- **Final completion:** 2027-06
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445076, "Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05445076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*